Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial.
第一作者:
P,Dusitanond
第一单位:
Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia.
作者:
医学主题词
血液凝固(Blood Coagulation);心血管疾病(Cardiovascular Diseases);内皮, 血管(Endothelium, Vascular);叶酸(Folic Acid);高半胱氨酸(Homocysteine);人类(Humans);炎症(Inflammation);脑缺血发作, 短暂性(Ischemic Attack, Transient);吡多辛(Pyridoxine);危险因素(Risk Factors);卒中(Stroke);维生素B12(Vitamin B 12);复合维生素B(Vitamin B Complex)
DOI
10.1161/01.STR.0000150494.91762.70
PMID
15569860
发布时间
2016-11-22
- 浏览7
Stroke
144-6页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



